InsiderTrades

Form 4 for CNXU Conexeu Sciences Inc.

Accepted 2026-06-22 13:25:42 ET · period of report 2026-06-18 · accession 0002137182-26-000003 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-06-22 13:25 2026-06-18 CNXU Wright Michael G. 10% M - OptEx $0.001 +250.0K 2.15M +13% +$250
DI 2026-06-22 13:25 2026-06-18 CNXU Wright Michael G. 10% M - OptEx $0.00 -250.0K 250.0K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-18 M A 250,000 $0.001 2,148,048 I N3GU Investments LLC — — (F1) The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.
2 Derivative Performance Warrants 2026-06-18 M D 250,000 $0.00 250,000 I N3GU Investments LLC $0.001 · — to 2030-06-05 250,000 Common Stock (F2) 900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. (F2) 900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. (F2) 900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. (F1) The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.